bibliographicCitation |
Serpa M, Sanabani SS, Bendit I, Seguro F, Xavier F, Barroso CB, Conchon M, Dorlhiac-Llacer PE. Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clin Med Insights Oncol. 2010 Dec 19;4():155–62. PMID: 21234296; PMCID: PMC3018898. |